<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795310</url>
  </required_header>
  <id_info>
    <org_study_id>XijingH-PF-20192074-C-1</org_study_id>
    <nct_id>NCT04795310</nct_id>
  </id_info>
  <brief_title>Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia</brief_title>
  <official_title>A Clinical Observation on the Efficacy and Safety of Pulsed Dye Laser and Intense Pulsed Light With Different Wavelength Bands in the Treatment of Facial Telangiectasia: a Retrospective, Self-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Facial telangiectasia is one of the common skin vascular lesions characterized by&#xD;
           dilated cutaneous vasculatures in the skin surface or mucous membranes. Lesions are&#xD;
           generally sensitive to exposure of cold, heat and sun. Those distinct small dilated&#xD;
           blood vessels are cosmetically disfiguring for patients which require an effective&#xD;
           solution. The traditional management options for facial telangiectasia include&#xD;
           cryotherapy, CO2 laser, topical agent, oral estrogens, electrosurgery, and radioactive&#xD;
           treatment. However, inadequate outcomes and severe adversaries are the major concerns to&#xD;
           patients and physicians.&#xD;
&#xD;
        2. Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the&#xD;
           superficial to middle layers of the dermis.&#xD;
&#xD;
           The intense pulsed light source is an alternative or supplement to the already existing&#xD;
           laser devices that are part of the laser surgeon's repertoire. The broad wavelength&#xD;
           spectrum and variable pulse duration allow greater penetration depths to be reached&#xD;
           without damaging surrounding tissue and thus enhance the versatility of this system.&#xD;
&#xD;
        3. This study aims to compare the clearance efficacy of facial telangiectasia using PDL&#xD;
           (595nm) with IPL configured by various wavelength bands, including M22 vascular filter&#xD;
           (530-650nm and 900-1200nm), M22 560 (560-1200nm), M22 590 (590-1200nm) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description has not been entered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity index of facial telangiectasia</measure>
    <time_frame>6months</time_frame>
    <description>minimal, focal visible telangiectasia in 5-10% of anatomic area&#xD;
focal visible telangiectasia in11-20% of an anatomic area&#xD;
focal visible telangiectasia in 21-30% of anatomic area&#xD;
visible telangiectasia in 31-40% of anatomic area&#xD;
visible telangiectasia in 41-50% of anatomic area&#xD;
moderately severe telangiectasia in 51-60% of anatomic area&#xD;
moderately severe telangiectasia in 61-70% of anatomic area&#xD;
severe telangiectasia in 71-80% of anatomic area&#xD;
severe telangiectasia in 81-90% of anatomic area&#xD;
severe and diffuse facial telangiectasia in entire anatomic area for facial telangiectasia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Telangiectasia</condition>
  <arm_group>
    <arm_group_label>Pulsed Dye Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intense Pulsed Light</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vascular wavelength bands of 530-650nm and 900-1200nm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulsed dye laser</intervention_name>
    <description>PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).&#xD;
IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment.</description>
    <arm_group_label>Intense Pulsed Light</arm_group_label>
    <arm_group_label>Pulsed Dye Laser</arm_group_label>
    <other_name>Intense pulsed light</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be clinically diagnosed with facial telangiectasia&#xD;
&#xD;
          -  No other external treatment was performed before the injury was treated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects with a recent history of exposure to sunlight&#xD;
&#xD;
          -  subjects allergic to topical anesthesia&#xD;
&#xD;
          -  subjects with scar constitution&#xD;
&#xD;
          -  subjects with skin malignant tumors or precancerous lesions&#xD;
&#xD;
          -  subjects with diabetes, heart disease, epilepsy, connective tissue disease, etc&#xD;
&#xD;
          -  subjects who Pregnant or breast feeding&#xD;
&#xD;
          -  subjects with recent skin infections (such as viruses, bacteria, etc.)&#xD;
&#xD;
          -  other methods are being used to treat subjects with similar diseases&#xD;
&#xD;
          -  subject who have taken isotretinoin A in the past year&#xD;
&#xD;
          -  subject with facial dermatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Wang, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Derpartment of Xijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Gang Wang</investigator_full_name>
    <investigator_title>Chief of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Facial Telangiectasia</keyword>
  <keyword>Pulsed dye laser (PDL)</keyword>
  <keyword>Intense Pulsed Light</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

